The sustained insider selling by a top officer at a rate of ~$1M/week is a strong negative signal, especially given the stock's high valuation and bullish analyst consensus. Monitor for Form 4 filings to confirm actual sales and watch for any material news that could explain the selling.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $56.07entry
- T+1 · 5mo ago +6.14%α +4.37% · $59.51
- T+5 · 5mo ago +2.57%α +1.90% · $57.51
- T+20 · 4mo ago +18.41%α +16.63% · $66.39
- T+60 · 2mo ago +0.95%α −2.32% · $56.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 35,000 common shares valued at approximately $1.85 million, to be executed through Morgan Stanley. The filing also reveals a heavy pattern of insider selling: Mulroy has sold over 260,000 shares in the past three weeks (May 15–June 10), totaling about $13.4 million, all via open-market sales after stock option exercises. This sustained selling by a top officer ahead of any public catalyst is a significant bearish signal.
Key Facts
- Officer Dennis Mulroy filed Form 144 to sell 35,000 shares (~$1.85M) on June 11, 2026.
- The filing reveals 18 prior open-market sales between May 15 and June 10, 2026, totaling ~260,000 shares and ~$13.4M.
- All sales were executed after stock option exercises, indicating a systematic plan to monetize equity.
- AnaptysBio has a $1.5B market cap and 94% analyst bullish consensus, making the insider selling pattern particularly notable.
Financial Impact
Officer sold ~$13.4M in shares over 3 weeks, with an additional $1.85M proposed; total ~$15.3M in planned sales.
Risk Factors
- Insider selling may indicate undisclosed negative developments (e.g., clinical trial setbacks, regulatory delays).
- Heavy option exercise and sale pattern could pressure the stock if selling continues.
- The 144 filing is an intent to sell; if the insider does not execute, the signal may be less severe.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005960 |
| Document: 0001950047-26-005960-index.html | 0001950047-26-005960 |
| Document: 0001950047-26-005960.txt | 0001950047-26-005960 |
Track record
28 reports on ANAB
10 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 13 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers